Reynolds I J, Snowman A M, Snyder S H
J Pharmacol Exp Ther. 1986 Jun;237(3):731-8.
The verapamil-like calcium channel modulator, (-)-[3H]desmethoxyverapamil binds to multiple sites in microsomal membrane preparations from brain and skeletal muscle. In brain the Kd values of the sites are 0.55 +/- 0.1 and 61.8 +/- 18 nM for the high and low affinity sites and the maximum binding values are 0.22 +/- 0.04 and 4.6 +/- 1.0 pmol/mg of protein, respectively. Equilibrium analysis of saturation data in skeletal muscle membranes shows only one site with an affinity of 7.2 +/- 0.8 nM and a maximum binding of 2.96 +/- 0.32 pmol/mg of protein. However, a low affinity site with an estimated Kd of 152 nM is indicated in dissociation kinetic studies. Dihydropyridine calcium channel modulators regulate the binding of desmethoxyverapamil in a temperature-dependent fashion with (+)-PN 200110 decreasing (-)-[3H]desmethoxyverapamil binding more at 0 degrees C than at higher temperatures and, at 37 degrees C, enhancing binding in skeletal muscle. The influence of (+)-desmethoxyverapamil on (+)-[3H]PN 200110 binding is unchanged by temperature variations, whereas interactions of the (-)-enantiomer are altered markedly with more inhibition at 0 degrees C than at higher temperatures and, in skeletal muscle, stimulation of binding at 37 degrees C. Dissociation studies indicate that the two sites labeled by (-)-[3H]-desmethoxyverapamil in skeletal muscle interact in a negative heterotropic cooperative fashion. Dihydropyridines appear to slow the dissociation of ligand from the low affinity site, whereas diltiazem accelerates the dissociation of (-)-[3H]desmethoxyverapamil from the high affinity site. These results suggest that the high and low affinity sites labeled by (-)-[3H]desmethoxyverapamil, respectively, represent the verapamil and diltiazem receptors in brain and skeletal muscle.
维拉帕米样钙通道调节剂(-)-[3H]去甲氧基维拉帕米可与脑和骨骼肌微粒体膜制剂中的多个位点结合。在脑中,高亲和力位点和低亲和力位点的Kd值分别为0.55±0.1和61.8±18 nM,最大结合值分别为0.22±0.04和4.6±1.0 pmol/mg蛋白质。骨骼肌膜中饱和数据的平衡分析显示只有一个位点,其亲和力为7.2±0.8 nM,最大结合量为2.96±0.32 pmol/mg蛋白质。然而,解离动力学研究表明存在一个估计Kd为152 nM的低亲和力位点。二氢吡啶类钙通道调节剂以温度依赖的方式调节去甲氧基维拉帕米的结合,(+)-PN 200110在0℃时比在较高温度下更能降低(-)-[3H]去甲氧基维拉帕米的结合,并且在37℃时增强骨骼肌中的结合。(+)-去甲氧基维拉帕米对(+)-[3H]PN 200110结合的影响不受温度变化的影响,而(-)-对映体的相互作用则明显改变,在0℃时比在较高温度下有更多抑制作用,并且在骨骼肌中,在37℃时刺激结合。解离研究表明,骨骼肌中由(-)-[3H]-去甲氧基维拉帕米标记的两个位点以负异向协同方式相互作用。二氢吡啶类似乎减缓了配体从低亲和力位点的解离,而地尔硫卓加速了(-)-[3H]去甲氧基维拉帕米从高亲和力位点的解离。这些结果表明,分别由(-)-[3H]去甲氧基维拉帕米标记的高亲和力位点和低亲和力位点代表脑和骨骼肌中的维拉帕米受体和地尔硫卓受体。